367 related articles for article (PubMed ID: 32573437)
1. Moyamoya disease factor RNF213 is a giant E3 ligase with a dynein-like core and a distinct ubiquitin-transfer mechanism.
Ahel J; Lehner A; Vogel A; Schleiffer A; Meinhart A; Haselbach D; Clausen T
Elife; 2020 Jun; 9():. PubMed ID: 32573437
[TBL] [Abstract][Full Text] [Related]
2. Moyamoya disease patient mutations in the RING domain of RNF213 reduce its ubiquitin ligase activity and enhance NFκB activation and apoptosis in an AAA+ domain-dependent manner.
Takeda M; Tezuka T; Kim M; Choi J; Oichi Y; Kobayashi H; Harada KH; Mizushima T; Taketani S; Koizumi A; Youssefian S
Biochem Biophys Res Commun; 2020 May; 525(3):668-674. PubMed ID: 32139119
[TBL] [Abstract][Full Text] [Related]
3. A new horizon of moyamoya disease and associated health risks explored through RNF213.
Koizumi A; Kobayashi H; Hitomi T; Harada KH; Habu T; Youssefian S
Environ Health Prev Med; 2016 Mar; 21(2):55-70. PubMed ID: 26662949
[TBL] [Abstract][Full Text] [Related]
4. MMD-associated
Bhardwaj A; Banh RS; Zhang W; Sidhu SS; Neel BG
Life Sci Alliance; 2022 May; 5(5):. PubMed ID: 35135845
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of E3 ubiquitin ligase RNF213 as an antimicrobial host determinant.
Zhang Y; Yuan Y; Jiang L; Liu Y; Zhang L
Front Cell Infect Microbiol; 2023; 13():1205355. PubMed ID: 37655297
[TBL] [Abstract][Full Text] [Related]
6. Moyamoya disease-associated protein mysterin/RNF213 is a novel AAA+ ATPase, which dynamically changes its oligomeric state.
Morito D; Nishikawa K; Hoseki J; Kitamura A; Kotani Y; Kiso K; Kinjo M; Fujiyoshi Y; Nagata K
Sci Rep; 2014 Mar; 4():4442. PubMed ID: 24658080
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and Functional Characterization of RNF213 (Mysterin) R4810K, a Susceptibility Mutation of Moyamoya Disease, in Angiogenesis In Vitro and In Vivo.
Kobayashi H; Matsuda Y; Hitomi T; Okuda H; Shioi H; Matsuda T; Imai H; Sone M; Taura D; Harada KH; Habu T; Takagi Y; Miyamoto S; Koizumi A
J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26126547
[TBL] [Abstract][Full Text] [Related]
8. RNF213 as the major susceptibility gene for Chinese patients with moyamoya disease and its clinical relevance.
Zhang Q; Liu Y; Zhang D; Wang R; Zhang Y; Wang S; Yu L; Lu C; Liu F; Zhou J; Zhang X; Zhao J
J Neurosurg; 2017 Apr; 126(4):1106-1113. PubMed ID: 27128593
[TBL] [Abstract][Full Text] [Related]
9. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development.
Liu W; Morito D; Takashima S; Mineharu Y; Kobayashi H; Hitomi T; Hashikata H; Matsuura N; Yamazaki S; Toyoda A; Kikuta K; Takagi Y; Harada KH; Fujiyama A; Herzig R; Krischek B; Zou L; Kim JE; Kitakaze M; Miyamoto S; Nagata K; Hashimoto N; Koizumi A
PLoS One; 2011; 6(7):e22542. PubMed ID: 21799892
[TBL] [Abstract][Full Text] [Related]
10. Moyamoya Disease and Spectrums of RNF213 Vasculopathy.
Bang OY; Chung JW; Kim DH; Won HH; Yeon JY; Ki CS; Shin HJ; Kim JS; Hong SC; Kim DK; Koizumi A
Transl Stroke Res; 2020 Aug; 11(4):580-589. PubMed ID: 31650369
[TBL] [Abstract][Full Text] [Related]
11. Temporal profile of the vascular anatomy evaluated by 9.4-tesla magnetic resonance angiography and histological analysis in mice with the R4859K mutation of RNF213, the susceptibility gene for moyamoya disease.
Kanoke A; Fujimura M; Niizuma K; Ito A; Sakata H; Sato-Maeda M; Morita-Fujimura Y; Kure S; Tominaga T
Brain Res; 2015 Oct; 1624():497-505. PubMed ID: 26315378
[TBL] [Abstract][Full Text] [Related]
12. Posterior circulation involvement and collateral flow pattern in moyamoya disease with the RNF213 polymorphism.
Kim WH; Kim SD; Nam MH; Jung JM; Jin SW; Ha SK; Lim DJ; Lee HB
Childs Nerv Syst; 2019 Feb; 35(2):309-314. PubMed ID: 30283986
[TBL] [Abstract][Full Text] [Related]
13. RNF213 loss-of-function promotes pathological angiogenesis in moyamoya disease via the Hippo pathway.
Ye F; Niu X; Liang F; Dai Y; Liang J; Li J; Wu X; Zheng H; Qi T; Sheng W
Brain; 2023 Nov; 146(11):4674-4689. PubMed ID: 37399508
[TBL] [Abstract][Full Text] [Related]
14. The Role of RNF213 4810G>A and 4950G>A Variants in Patients with Moyamoya Disease in Korea.
Park YS; An HJ; Kim JO; Kim WS; Han IB; Kim OJ; Kim NK; Kim DS
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29160859
[TBL] [Abstract][Full Text] [Related]
15. Temporal profile of magnetic resonance angiography and decreased ratio of regulatory T cells after immunological adjuvant administration to mice lacking RNF213, a susceptibility gene for moyamoya disease.
Kanoke A; Fujimura M; Niizuma K; Fujimura T; Kakizaki A; Ito A; Sakata H; Sato-Maeda M; Kure S; Tominaga T
Brain Res; 2016 Jul; 1642():1-9. PubMed ID: 26972532
[TBL] [Abstract][Full Text] [Related]
16. RNF213 Rare Variants in Slovakian and Czech Moyamoya Disease Patients.
Kobayashi H; Brozman M; Kyselová K; Viszlayová D; Morimoto T; Roubec M; Školoudík D; Petrovičová A; Juskanič D; Strauss J; Halaj M; Kurray P; Hranai M; Harada KH; Inoue S; Yoshida Y; Habu T; Herzig R; Youssefian S; Koizumi A
PLoS One; 2016; 11(10):e0164759. PubMed ID: 27736983
[TBL] [Abstract][Full Text] [Related]
17. Molecular structure and function of mysterin/RNF213.
Morito D
J Biochem; 2024 Apr; 175(5):495-505. PubMed ID: 38378744
[TBL] [Abstract][Full Text] [Related]
18. Loss of mitochondrial ClpP, Lonp1, and Tfam triggers transcriptional induction of Rnf213, a susceptibility factor for moyamoya disease.
Key J; Maletzko A; Kohli A; Gispert S; Torres-Odio S; Wittig I; Heidler J; Bárcena C; López-Otín C; Lei Y; West AP; Münch C; Auburger G
Neurogenetics; 2020 Jul; 21(3):187-203. PubMed ID: 32342250
[TBL] [Abstract][Full Text] [Related]
19. In silico explanation for the causalities of deleterious RNF213 SNPs in Moyamoya disease and insulin resistance.
Sarkar P; Thirumurugan K
Comput Biol Chem; 2021 Jun; 92():107488. PubMed ID: 33930741
[TBL] [Abstract][Full Text] [Related]
20. De novo variants in RNF213 are associated with a clinical spectrum ranging from Leigh syndrome to early-onset stroke.
Brunet T; Zott B; Lieftüchter V; Lenz D; Schmidt A; Peters P; Kopajtich R; Zaddach M; Zimmermann H; Hüning I; Ballhausen D; Staufner C; Bianzano A; Hughes J; Taylor RW; McFarland R; Devlin A; Mihaljević M; Barišić N; Rohlfs M; Wilfling S; Sondheimer N; Hewson S; Marinakis NM; Kosma K; Traeger-Synodinos J; Elbracht M; Begemann M; Trepels-Kottek S; Hasan D; Scala M; Capra V; Zara F; van der Ven AT; Driemeyer J; Apitz C; Krämer J; Strong A; Hakonarson H; Watson D; Mayr JA; Prokisch H; Meitinger T; Borggraefe I; Spiegler J; Baric I; Paolini M; Gerstl L; Wagner M
Genet Med; 2024 Feb; 26(2):101013. PubMed ID: 37924258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
